First high-precision measurement of potential dynamics inside reactor-grade fusion plasma
Achieved with a high-efficiency accelerator and non-contact diagnostics
2025-11-13
(Press-News.org)
Nuclear fusion, which operates on the same principle that powers the Sun, is expected to become a sustainable energy source for the future. To achieve fusion power generation, it is essential to confine plasma at temperatures exceeding one hundred million degrees using a magnetic field and to maintain this high-energy state stably. A key factor in accomplishing this is the electric potential inside the plasma. This potential governs the transport of particles and energy within the plasma and plays a crucial role in establishing a state in which energy is effectively confined and prevented from escaping. Therefore, accurately measuring the internal plasma potential is essential for improving the performance of future fusion reactors.
A non-contact diagnostic technique called the heavy ion beam probe (HIBP) is used to measure plasma potential directly. In this method, negatively charged gold ions (Au⁻) are accelerated and injected into the plasma. By detecting how their charge state changes through interactions with the plasma, the electric potential inside the plasma can be inferred with high sensitivity. However, obtaining high-precision signals requires a strong and stable ion beam. Although advances in negative ion sources have increased the available beam current, efficiently transporting and injecting high-current beams into the accelerator has remained difficult, limiting the achievable diagnostic precision.
In the Large Helical Device (LHD), the HIBP system has been developed to measure electric potential in plasmas. In this system, a gold negative ion (Au⁻) beam is injected into a tandem accelerator, converted into a gold positive ion (Au⁺) beam, and further accelerated up to 6 mega–electron volts (MeV) at the accelerator’s exit before being injected into the plasma. The beam that becomes Au²⁺ through collisions with the plasma passes through the magnetized plasma, and by measuring the energy difference between the incident Au⁺ beam and the Au²⁺ beam after it traverses the plasma, the electric potential at the position where Au²⁺ was produced can be determined. To obtain a clear and precise potential signal, a higher injection current into the plasma is required. Although the output current of the Au⁻ ion source had been successfully increased, the injection beam current into the tandem accelerator could not be increased in direct proportion, which remained a significant challenge.
To identify the cause of this limitation, the research team analyzed the heavy-ion beam transport efficiency on the low-energy side — from the negative ion source to the entrance of the tandem accelerator — using the ion-beam transport simulation code IGUN. The simulations revealed that when the Au⁻ beam current is below 10 microamperes (µA), the beam can pass through the entrance slit during the acceleration, as shown in Fig. 2(a). However, at higher beam currents, the beam expands due to the space-charge effect, resulting in significant beam loss before entering the tandem accelerator, as shown in Fig. 2(b). For heavy-ion beams such as gold, this space-charge-induced limitation becomes particularly pronounced even if the output current from the negative ion source is increased. To improve beam transport efficiency, the team proposed using the multistage accelerator located between the ion source and the tandem accelerator, not only for acceleration but also as an electrostatic lens by optimizing its voltage distribution, as illustrated in Fig. 2(c). Numerical simulations demonstrated that by optimizing the voltage allocation of the multistage electrodes, a high-transmission region exceeding 95 % could be achieved, as shown in Fig. 3, significantly enhancing the beam transport efficiency compared with the conventional voltage configuration (blue circle). Subsequent plasma experiments confirmed the validity of this approach, showing that the Au⁻ beam current injected into the accelerator increased by a factor of two to three.
As the Au⁻ beam current increased, the corresponding Au⁺ beam injected into the plasma also increased, thereby expanding the measurable range of plasma potential in the LHD up to a line-averaged electron density of 1.75×10¹⁹ m⁻³. The enhanced signal clarity enabled the detection of temporal transitions in the internal plasma potential distribution associated with changes in the plasma confinement state (Fig. 4). At t = 4.0 s, the plasma was sustained by electron cyclotron heating; at t = 6.1 s, 0.1 s after the heating was turned off; and at t = 7.0 s, by 180 keV neutral beam injection. The results revealed a rapid overall decrease in plasma potential immediately after the termination of electron heating, followed by a gradual flattening of the potential profile. Because variations in plasma potential strongly influence plasma confinement performance, these experimental data are indispensable for improving predictive models of plasma behavior and for establishing new confinement frameworks in fusion research.
The method developed in this study provides a practical and compact solution for optimizing heavy ion beam transport and can be extended to other diagnostic systems and accelerator applications that require high-intensity beams. Furthermore, achieving high-precision and reproducible measurements of the internal potential structure in reactor-grade fusion plasmas is extremely important as a fundamental database for future research on plasma control and reactor design.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-11-13
CHAMPAIGN, Ill. — A naturally occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report. The protein, FGD3, contributes to the rupture of cancer cells disrupted by these drugs, boosting their effectiveness and enhancing anticancer immunotherapies.
The discovery is described in the Journal of Experimental & Clinical Cancer Research.
The new findings were the happy result of experiments involving ErSO, an experimental drug that killed 95-100% of estrogen-receptor-positive ...
2025-11-13
A widely-used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new Cochrane review.
The review examined the effects of low doses of colchicine, a drug used to treat gout, and found no increase in serious side effects.
Cardiovascular disease is often driven by chronic low-grade inflammation, which contributes to recurrent cardiovascular events such as heart attacks and strokes. Colchicine has anti-inflammatory properties that make it a promising option for people with heart disease.
A promising effect on cardiovascular risk
The review included 12 randomized controlled trials involving nearly 23,000 ...
2025-11-13
EMBARGOED: Hold for release until Wednesday, Nov. 12 at 18:30 ET / 23:30 UK time
Headache disorders affect 3 billion people worldwide—nearly one in every three people, ranking sixth for health loss in 2023
Women experienced more than twice the headache-related health loss of men and spent a greater share of their lives with headache symptoms.
Migraine caused nearly 90% of all disability linked to headache disorders, even though tension-type headache was more common.
More than one-fifth of the global headache burden ...
2025-11-13
ROCHESTER, Minn. — Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking problems associated with Alzheimer's disease years before symptoms appear. The research, published in The Lancet Neurology, builds on decades of data from the Mayo Clinic Study of Aging — one of the world's most comprehensive population-based studies of brain health.
The study found that women have a higher lifetime risk than men of developing dementia and mild cognitive impairment (MCI), a transitional stage between healthy aging and dementia ...
2025-11-13
Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds a US study published by The BMJ today.
Extended treatment was also linked to higher rates of major bleeding (a common side effect of anti-clotting drugs) but the authors say continued use results in an overall “net clinical benefit.”
Guidelines recommend anti-clotting treatment for at least 3-6 months for patients with venous thromboembolism ...
2025-11-13
Exposing children to e-cigarettes compromises their human rights. These products should be regulated in a way that puts children’s best interests first and protects them from the harms associated with nicotine consumption in all its forms, argue experts in The BMJ today.
Children are now using e-cigarettes at higher rates than adults, write Tom Gatehouse and colleagues. Globally, the World Health Organization (WHO) estimates that 7.2% of children aged 13-15 currently use e-cigarettes. Data indicate use in this group is nine times that of adults, in countries which monitor both groups.
As ...
2025-11-13
The rate of high blood pressure (hypertension) in children and adolescents under 19 has nearly doubled, increasing from about 3% in 2000 to over 6% in 2020.
More than 9% of children and adolescents have masked hypertension — high blood pressure that only shows up with out-of-office tests, meaning hypertension could be undetected during regular checkups.
Nearly 19% of children and adolescents with obesity have hypertension, eight times higher than the prevalence of hypertension in those considered a healthy weight.
Approximately 8% of children and adolescents now have prehypertension, a warning sign of potential progression to hypertension, which ...
2025-11-13
Seattle, United States & Seoul, Republic of Korea—PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® Multi-dose is manufactured by EuBiologics Co., LTD, Republic of Korea. The results, published in The Lancet Global Health, demonstrate that EuTYPH-C Inj.® Multi-dose is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa.
The study was conducted at sites in Kenya and Senegal in healthy ...
2025-11-13
Global carbon emissions from fossil fuels are projected to rise by 1.1% in 2025 – reaching a record high, according to new research by the Global Carbon Project.
The 2025 Global Carbon Budget projects 38.1 billion tonnes of fossil carbon dioxide (CO2) emissions this year.
Decarbonisation of energy systems is progressing in many countries – but this is not enough to offset the growth in global energy demand.
With projected emissions from land-use change (such as deforestation) down to 4.1 billion ...
2025-11-13
A fundamental rethink of how the NHS trains its future workforce is urgently needed, according to a new paper from the Higher Education Policy Institute (www.hepi.ac.uk), Rethinking Placement: Increasing Clinical Placement Efficacy for a Sustainable NHS Future (HEPI Report 194).
The paper, written by senior leaders from the University of East London (UEL), argues that the National Health Service (NHS) cannot achieve its ambitious workforce goals without bold system-wide reform of how students gain real-world experience – the essential bridge between classroom learning and frontline care.
The HEPI Report, which has been published with the support of the Council for Deans ...
LAST 30 PRESS RELEASES:
[Press-News.org] First high-precision measurement of potential dynamics inside reactor-grade fusion plasma
Achieved with a high-efficiency accelerator and non-contact diagnostics